SCHEMBL1744622

SCHEMBL1744622

O=C(O)CCc1ccc(OCc2ccc(C(=O)c3ccccc3)cc2)cc1

nearest known ligand 0.80

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 14/20 0.80
FFAR4 Q5NUL3 7/20 0.80
SRD5A2 P31213 2/20 0.71
ALDH1A1 P00352 2/20 0.69
HTT P42858 2/20 0.69
SMN1; SMN2 Q16637 2/20 0.69
L3MBTL1 Q9Y468 1/20 0.69
GAA P10253 1/20 0.66
MAPT P10636 1/20 0.66
RAB9A P51151 1/20 0.66
AKR1B1 P15121 1/20 0.63
PPARG P37231 1/20 0.61
PPARA Q07869 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1744939 0.89 FFAR1 (1.00) FFAR1FFAR4AKR1B1
Benzyloxyphenylpropanoic Acid SCHEMBL1134648 0.89 FFAR1 (1.00) FFAR1FFAR4AKR1B1
SCHEMBL435227 0.89 FFAR1 (0.74) FFAR1FFAR4AKR1B1
SCHEMBL1746654 0.89 FFAR1 (0.67) FFAR1FFAR4SRD5A2ALDH1A1HTT
Benzyloxyphenylpropanoic Acid SCHEMBL30117578 0.88 FFAR1 (0.97) FFAR1FFAR4AKR1B1
SCHEMBL2772440 0.88 FFAR1 (1.00) FFAR1FFAR4AKR1B1
SCHEMBL1747202 0.86 SMN1; SMN2 (0.67) FFAR1FFAR4SRD5A2ALDH1A1HTT
SCHEMBL402300 0.86 SRD5A2 (0.87) FFAR1FFAR4SRD5A2ALDH1A1HTT
SCHEMBL15239095 0.86 FFAR1 (0.76) FFAR1FFAR4AKR1B1
SCHEMBL433667 0.86 FFAR1 (0.76) FFAR1FFAR4ALDH1A1HTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1559422-B1 RECEPTOR FUNCTION CONTROLLING AGENT TAKEDA PHARMACEUTICAL (JP) 2014-04-30 EP disclosed
EP-1559422-B1 RECEPTOR FUNCTION CONTROLLING AGENT TAKEDA PHARMACEUTICAL (JP) 2014-04-30 EP disclosed
EP-2385032-A1 GPR40 Receptor function regulator Takeda Pharmaceutical Company Limited (JP) 2011-11-09 EP disclosed
EP-2385032-A1 GPR40 Receptor function regulator Takeda Pharmaceutical Company Limited (JP) 2011-11-09 EP disclosed
US-7960369-B2 Receptor function regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-06-14 US disclosed
US-7960369-B2 Receptor function regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-06-14 US disclosed
US-7960369-B2 Receptor function regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-06-14 US disclosed
US-20090012093-A1 Receptor Function Regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-01-08 US disclosed
US-20090012093-A1 Receptor Function Regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-01-08 US disclosed
US-20090012093-A1 Receptor Function Regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-01-08 US disclosed
EP-1559422-A1 RECEPTOR FUNCTION CONTROLLING AGENT Takeda Pharmaceutical Company Limited (JP) 2005-08-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090012093-A1 Receptor Function Regulator GPR119, GIPR, INSR FFAR1 33/4885FFAR4 44/4885SRD5A2 1727/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.